Sentence examples for injection depots from inspiring English sources

This group is selected to study the US-guided injection depots of 99mTc-nanocolloid by means of SPECT/CT without making additional SPECT/CT scans.

There are several possibilities to explain the observed distance deviation between the 99mTc-nanocolloid injection depot and the 125I seed on SPECT/CT.

In these patients, additional SPECT/CT was acquired to measure the distance between the 99mTc-nanocolloid injection depot and the 125I seed.

In the following 36 125I seeds (34 patients), the average difference between the 125I seed and the centre of the 99mTc-nanocolloid injection depot was 10.9 ± 6.8 mm.

The ten injections with more measurements resulted, after measuring the distance between the 99mTc-nanocolloid injection depot and the 125I seed, in a mean distance of 10.0 mm instead of 11.2 mm in the other 26 injections.

Retrospective analysis of the data showed a possible relation between the number of measurements made by the freehand SPECT and the distance between the 99mTc-nanocolloid injection depot and the 125I seed.

In the retrospective study, the average distance between the 125I seed and the centre of the 99mTc-nanocolloid injection depot as measured in SPECT/CT was 9.7 ± 6.5 mm and was not significantly different compared to the freehand SPECT-guided group (two-sample Student's t test, p = 0.52).

When only the 125I seeds with a depth of <26 mm are taken into consideration (25/36 125I seeds), the average distance between the 99mTc-nanocolloid injection depot and the 125I seed is 8.2 mm (SD 5.1 mm, range 0 to 20 mm) This is less than the average distance measured on the SPECT/CT scans for all US-guided injections (group 2). Figure 5 Distance vs. depth.

The zinc gradually separates from the multihexamers resulting in a slow, continuous and predictable delivery of insulin degludec monomers from the subcutaneous injection depot into the circulation.

31 The change has the effect of enabling dihexameric complexes to form in the injection depot, as well as enabling reversible albumin binding.

Since poor treatment adherence is a major risk for relapse, the use of long-acting injection ("depot") formulations of antipsychotics should have advantages in maintenance treatment of patients with schizophrenia with a history of non-compliance and relapse [ 1- 3].